Turns out, the usage of marijuana by kidney donors has no measurable effect on the outcome of kidney transplants for donors or recipients.
A new study in Clinical Kidney Journal reviewed living kidney transplants performed between January 2000 and May 2016 in a single academic institution. Donor and recipient groups were each divided into two groups by donor marijuana usage, comparing the outcomes of the transplants using a variety of tests.
Researchers reviewed 294 living donor medical records, including 31 marijuana using donors. They also reviewed 230 living kidney recipient records, including 27 cannabis-using kidney recipients. The use of grass in the United States has been steadily increasing over the last 10 years. Marijuana use has more than doubled between 2001 and 2013, with 54.1 per cent of adolescents claiming to have initiated its use by the age of 21.
There is a shortage of kidneys available for transplantation. As of 2018, there are nearly 100,000 patients on the waiting list for donor kidney transplants, with an average wait time of 3 to 10 years depending on region and blood type. Some patients do not survive long enough on dialysis to receive a transplant.
Based on National Kidney Registry recommendations that exclude substance abusers from the donation, transplant institutions may refuse live kidney donors who have a history of marijuana use. However, there was previously no evidence pertaining specifically to the donor or recipient outcomes.
The results show no difference in donor or recipient preoperative characteristics or postoperative outcomes based upon donor marijuana use, indicating that there were no long-term differences in kidney function between those who used marijuana and those who did not.
"A significant shortage in available potential kidney donors exists," said the study's lead author, Duane Baldwin.
"Our goal with this study was to start a conversation on this topic and to encourage other centres to study this important question. It is our hope that considering marijuana using donors could ultimately save lives," added Baldwin.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
